Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 1997Transplantation

A Pilot Trial of Recombinant Human Interleukin-10 in Kidney Transplant Recipients Receiving Okt3 Induction Therapy1,2

View Full Paper
Ask AI
Bookmark
Share

Authors

KWKarl Martin WissingEMEmmanuel MorélonCLChristophe Legendre

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wissing et al. (1997) studied this question.

synapsesocial.com/papers/6aa027c06fb3bd2270351771https://doi.org/10.1097/00007890-199710150-00012
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function1992 · 370 citations
  2. 2Pancreatic islet production of murine interleukin-10 does not inhibit immune-mediated tissue destruction.1994 · 121 citations
  3. 3Direct demonstration of binding of anti-Leu 4 antibody to the 40 kDa Fc receptor on monocytes as a prerequisite for anti-Leu 4-induced T cell mitogenesis.1987 · 26 citations
  4. 4Human interleukin-10 can directly inhibit T-cell growth1993 · 279 citations
  5. 5Interleukin‐10 differentially regulates cytokine inhibitor and chemokine release from blood mononuclear cells and fibroblasts1995 · 124 citations